Literature DB >> 35523880

Checkpoint inhibitors in a marriage: consented or arranged?

Patrick Brest1, Sadal Refae2, Baharia Mograbi1, Jean-Marc Ferrero3, Christophe Bontoux4, Paul Hofman1,4, Gerard Milano5.   

Abstract

There is currently a strong development of therapeutic combinations with checkpoint inhibitors (CPIs). The most promising combinations with CPIs concern anti-angiogenic agents and BRAF/MEK inhibitors. The timing of the initiation of the combination should be particularly well investigated for chemotherapy. Combinations between CPIs raise questions about risk/benefit ratio and overall clinical activity.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35523880      PMCID： PMC9174256          DOI： 10.1038/s41416-022-01820-8

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   9.075


  13 in total

1.  Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.

Authors:  Riki Okita; Ai Maeda; Katsuhiko Shimizu; Yuji Nojima; Shinsuke Saisho; Masao Nakata
Journal:  Oncol Rep       Date:  2019-06-03       Impact factor: 3.906

Review 2.  Enhancing anti-tumour efficacy with immunotherapy combinations.

Authors:  Funda Meric-Bernstam; James Larkin; Josep Tabernero; Chiara Bonini
Journal:  Lancet       Date:  2020-12-04       Impact factor: 79.321

3.  BRAF inhibition alleviates immune suppression in murine autochthonous melanoma.

Authors:  Shannon M Steinberg; Peisheng Zhang; Brian T Malik; Andrea Boni; Tamer B Shabaneh; Katelyn T Byrne; David W Mullins; Constance E Brinckerhoff; Marc S Ernstoff; Marcus W Bosenberg; Mary Jo Turk
Journal:  Cancer Immunol Res       Date:  2014-09-02       Impact factor: 11.151

4.  Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

Authors:  Christina Pfirschke; Camilla Engblom; Steffen Rickelt; Virna Cortez-Retamozo; Christopher Garris; Ferdinando Pucci; Takahiro Yamazaki; Vichnou Poirier-Colame; Andita Newton; Younes Redouane; Yi-Jang Lin; Gregory Wojtkiewicz; Yoshiko Iwamoto; Mari Mino-Kenudson; Tiffany G Huynh; Richard O Hynes; Gordon J Freeman; Guido Kroemer; Laurence Zitvogel; Ralph Weissleder; Mikael J Pittet
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

5.  PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.

Authors:  Jianfeng Shen; Wei Zhao; Zhenlin Ju; Lulu Wang; Yang Peng; Marilyne Labrie; Timothy A Yap; Gordon B Mills; Guang Peng
Journal:  Cancer Res       Date:  2018-11-27       Impact factor: 12.701

6.  Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors.

Authors:  Adam C Palmer; Benjamin Izar; Haeun Hwangbo; Peter K Sorger
Journal:  Clin Cancer Res       Date:  2022-01-15       Impact factor: 13.801

7.  CDK4/6 inhibition triggers anti-tumour immunity.

Authors:  Shom Goel; Molly J DeCristo; April C Watt; Haley BrinJones; Jaclyn Sceneay; Ben B Li; Naveed Khan; Jessalyn M Ubellacker; Shaozhen Xie; Otto Metzger-Filho; Jeremy Hoog; Matthew J Ellis; Cynthia X Ma; Susanne Ramm; Ian E Krop; Eric P Winer; Thomas M Roberts; Hye-Jung Kim; Sandra S McAllister; Jean J Zhao
Journal:  Nature       Date:  2017-08-16       Impact factor: 49.962

Review 8.  Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation.

Authors:  Robert L Ferris; Heinz-Josef Lenz; Anna Maria Trotta; Jesús García-Foncillas; Jeltje Schulten; François Audhuy; Marco Merlano; Gerard Milano
Journal:  Cancer Treat Rev       Date:  2017-12-02       Impact factor: 12.111

Review 9.  PD-L1 regulation revisited: impact on immunotherapeutic strategies.

Authors:  Giulia Lucibello; Baharia Mograbi; Gerard Milano; Paul Hofman; Patrick Brest
Journal:  Trends Mol Med       Date:  2021-06-26       Impact factor: 11.951

Review 10.  Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.

Authors:  Won Suk Lee; Hannah Yang; Hong Jae Chon; Chan Kim
Journal:  Exp Mol Med       Date:  2020-09-11       Impact factor: 8.718
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.